Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Files Blockbuster Hopeful Shingrix With FDA

Executive Summary

The shingles vaccine is considered one of the products with the biggest commercial potential for GSK in the near-term.

Advertisement

Related Content

GSK US Pharma President Jack Bailey On A “Dynamic” 2017
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
GSK’s New CEO Designate Walmsley Fortifies Volume Growth Strategy
GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax
GSK's Vaccines Chief Slaoui To Follow Witty Out The Door
GSK pushes more data for shingles vaccine, but no filing yet

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097530

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel